Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2014.00300 Oncology Erratum Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel) Frontiers Production Office 1 * 1Frontiers Production Office, Frontiers, Switzerland

Approved by: Oncology Editorial Office, Frontiers, Switzerland

 *Correspondence: production.office@frontiersin.org

This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology.

 30 10 2014 2014 4 300 14 10 2014 14 10 2014 Copyright © 2014 Frontiers Production Office. 2014

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 An erratum on Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel) by Blais N, Hirsh V. Front Oncol (2014) 4:177. doi:10.3389/fonc.2014.00177 metastatic non-small cell lung carcinoma solvent-based paclitaxel nab-paclitaxel pemetrexed histology clinical trials Reason for Erratum

In Table 2, the Median OS values (in months) in the column ≥70 years were changed due to a typesetting error. This error does not change the scientific conclusions of the article in any way. The publisher apologizes for this error and the correct version of Table 2 appears below.

Select efficacy outcomes from the Phase III trial of nab-paclitaxel plus carboplatin in NSCLC.

Treatment ITT (41)
 ≥70 years (42)
 Histology (43)
SCC
 NSCC
nab-P/C sb-P/C nab-P/C sb-P/C nab-P/C sb-P/C nab-P/C sb-P/C
n 514 524 74 82 229 221 292 310
ORR (%) 33 25 34 24 41 24 26 25
Response rate ratio 1.313 1.385 1.680 1.034
p-Value 0.005 0.196 <0.001 0.808
Median PFS (months) 6.3 5.8 8.0 6.8 5.6 5.7 6.9 6.5
HR 0.902 0.687 0.865 0.933
p-Value 0.214 0.134 0.245 0.532
Median OS (months) 12.1 11.2 19.9 10.4 10.7 9.5 13.1 13.0
HR 0.922 0.583 0.890 0.950
p-Value 0.271 0.009 0.284 0.611

HR, hazard ratio; IIT, intent-to-treat; nab-P/C, nab-paclitaxel + carboplatin; NSCC, non-squamous cell carcinoma; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; sb-P/C, solvent-based paclitaxel + carboplatin; SCC, squamous cell carcinoma.